Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805).

Stein MN, Chen YH, Carducci MA, Hudes GR, Lerma PM, Tan WW, Dalune R, Rowland KM, Kuzel TM, DiPaola RS.

Am J Clin Oncol. 2019 Apr;42(4):375-381. doi: 10.1097/COC.0000000000000526.

PMID:
30789412
2.

Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.

Wong YN, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams SD, Fisch MJ, Cella D, Carducci MA, Wilding G.

Clin Genitourin Cancer. 2018 Apr;16(2):e315-e322. doi: 10.1016/j.clgc.2017.10.001. Epub 2017 Oct 16.

3.

Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells.

Lee HO, Mustafa A, Hudes GR, Kruger WD.

PLoS One. 2015 Jul 2;10(7):e0131464. doi: 10.1371/journal.pone.0131464. eCollection 2015.

4.

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.

Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA.

Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50. doi: 10.1007/s00280-014-2539-0. Epub 2014 Aug 7.

5.

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.

Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR.

J Clin Oncol. 2014 Jun 20;32(18):1895-901. doi: 10.1200/JCO.2013.53.2465. Epub 2014 May 12.

6.

PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.

MacFarlane AW 4th, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS.

Cancer Immunol Res. 2014 Apr;2(4):320-31. doi: 10.1158/2326-6066.CIR-13-0133. Epub 2013 Nov 25.

7.

A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.

Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB.

Oncologist. 2014 Apr;19(4):354-5. doi: 10.1634/theoncologist.2014-0020. Epub 2014 Mar 27.

8.

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.

Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu Y, Schwartz JD, Thompson JA.

Cancer. 2014 Jun 1;120(11):1647-55. doi: 10.1002/cncr.28634. Epub 2014 Feb 27.

9.

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.

de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN.

Clin Cancer Res. 2014 Apr 1;20(7):1925-34. doi: 10.1158/1078-0432.CCR-13-1869. Epub 2014 Feb 17.

10.

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ.

Cancer Chemother Pharmacol. 2014 Jan;73(1):151-61. doi: 10.1007/s00280-013-2333-4. Epub 2013 Nov 13.

11.

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).

Meulenbeld HJ, de Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, Zandvliet AS, Ebbinghaus SW, Hudes GR, de Wit R.

Cancer Chemother Pharmacol. 2013 Oct;72(4):909-16. doi: 10.1007/s00280-013-2250-6. Epub 2013 Aug 7.

PMID:
23921574
12.

Reply to S. Buti and S. Culine.

Wong YN, Plimack ER, Litwin S, Vaughn D, Lee J, Song W, Hudes GR.

J Clin Oncol. 2013 Apr 20;31(12):1615-6. No abstract available.

13.

Testicular cancer.

Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):502-35. No abstract available.

PMID:
22491049
14.

Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.

Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA.

J Clin Oncol. 2012 Apr 20;30(12):1371-7. doi: 10.1200/JCO.2011.36.4133. Epub 2012 Mar 19.

PMID:
22430274
15.

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR.

Eur J Cancer. 2012 Jan;48(1):85-93. doi: 10.1016/j.ejca.2011.10.014. Epub 2011 Nov 28.

PMID:
22129890
16.

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR.

Ann Oncol. 2012 May;23(5):1234-40. doi: 10.1093/annonc/mdr399. Epub 2011 Sep 19.

17.

Selecting targeted therapies for patients with renal cell carcinoma.

Plimack ER, Hudes GR.

J Natl Compr Canc Netw. 2011 Sep 1;9(9):997-1006; quiz 1007.

PMID:
21917624
18.

Kidney cancer.

Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Sep 1;9(9):960-77. No abstract available. Erratum in: J Natl Compr Canc Netw. 2011 Nov 1;9(11):xlv.

PMID:
21917622
19.

Serum amino acid levels as a biomarker for renal cell carcinoma.

Mustafa A, Gupta S, Hudes GR, Egleston BL, Uzzo RG, Kruger WD.

J Urol. 2011 Oct;186(4):1206-12. doi: 10.1016/j.juro.2011.05.085. Epub 2011 Aug 17.

20.

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.

Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S.

J Natl Compr Canc Netw. 2011 Feb;9 Suppl 1:S1-29.

21.

Global reactivation of epigenetically silenced genes in prostate cancer.

Ibragimova I, Ibáñez de Cáceres I, Hoffman AM, Potapova A, Dulaimi E, Al-Saleem T, Hudes GR, Ochs MF, Cairns P.

Cancer Prev Res (Phila). 2010 Sep;3(9):1084-92. doi: 10.1158/1940-6207.CAPR-10-0039. Epub 2010 Aug 10.

22.

Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma.

Pei J, Feder MM, Al-Saleem T, Liu Z, Liu A, Hudes GR, Uzzo RG, Testa JR.

Genes Chromosomes Cancer. 2010 Jul;49(7):610-9. doi: 10.1002/gcc.20771.

23.

Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG.

Am J Clin Oncol. 2010 Dec;33(6):614-8. doi: 10.1097/COC.0b013e3181c4454d.

PMID:
20142724
24.

Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.

Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J.

Semin Oncol. 2009 Dec;36 Suppl 3:S26-36. doi: 10.1053/j.seminoncol.2009.10.013. Review.

PMID:
19963097
25.

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.

Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang L, Tran-Thanh D, Pham NA, Tsao MS, Hedley D, Dancey JE, Moore MJ.

Am J Clin Oncol. 2010 Dec;33(6):609-13. doi: 10.1097/COC.0b013e3181beac33.

PMID:
20042973
26.

NCCN clinical practice guidelines in oncology: kidney cancer.

Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.

J Natl Compr Canc Netw. 2009 Jun;7(6):618-30. No abstract available.

PMID:
19555584
27.

NCCN clinical practice guidelines in oncology: testicular cancer.

Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.

J Natl Compr Canc Netw. 2009 Jun;7(6):672-93. No abstract available.

PMID:
19555582
28.

Targeting mTOR in renal cell carcinoma.

Hudes GR.

Cancer. 2009 May 15;115(10 Suppl):2313-20. doi: 10.1002/cncr.24239. Review.

29.

Bladder cancer.

Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Jan;7(1):8-39. No abstract available.

PMID:
19176203
30.

NCCN Task Force Report: mTOR inhibition in solid tumors.

Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB 3rd, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ Jr, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y.

J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20; quiz S21-2. Review.

PMID:
18926092
31.

mTOR as a target for therapy of renal cancer.

Hudes GR.

Clin Adv Hematol Oncol. 2007 Oct;5(10):772-4. No abstract available.

PMID:
17998894
32.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI.

Lancet Oncol. 2007 Nov;8(11):975-84. Epub 2007 Oct 23.

PMID:
17959415
33.

Sunitinib efficacy against advanced renal cell carcinoma.

Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G.

J Urol. 2007 Nov;178(5):1883-7. Epub 2007 Sep 17.

PMID:
17868732
34.

Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.

J Clin Oncol. 2007 Sep 1;25(25):3958-64.

PMID:
17761980
35.

Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model.

McDermott RS, Kloth DD, Wang H, Hudes GR, Langer CJ.

J Support Oncol. 2006 Nov-Dec;4(10):524-9.

PMID:
17136870
36.

Kidney cancer. Clinical practice guidelines in oncology.

Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):1072-81. No abstract available.

PMID:
17112454
37.

Testicular cancer. Clinical practice guidelines in oncology.

Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar KS, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):1038-58. No abstract available.

PMID:
17112452
38.

Bladder cancer. Clinical guidelines in oncology.

Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):984-1014. No abstract available.

PMID:
17112448
39.

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.

JAMA. 2006 Jun 7;295(21):2516-24.

PMID:
16757724
40.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI.

J Clin Oncol. 2006 Jan 1;24(1):16-24. Epub 2005 Dec 5.

PMID:
16330672
41.

Kidney cancer. Clinical practice guidelines.

Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili R, Pohar KS, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jan;3(1):84-93. No abstract available.

PMID:
19813325
42.

Testicular cancer. Clinical practice guidelines.

Motzer RJ, Bahnson RR, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jan;3(1):52-76. No abstract available.

PMID:
19813323
43.

Bladder cancer. Clinical practice guidelines in oncology.

Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Seigne J, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jan;3(1):4-5, 19-34.

PMID:
19813320
44.

Cranial nerve deficits in patients with metastatic prostate carcinoma: clinical features and treatment outcomes.

McDermott RS, Anderson PR, Greenberg RE, Milestone BN, Hudes GR.

Cancer. 2004 Oct 1;101(7):1639-43.

45.

Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.

Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes GR.

Clin Cancer Res. 2004 Jul 15;10(14):4645-51.

46.

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.

Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.

Cancer. 2004 Apr 15;100(8):1639-45.

47.

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML.

J Clin Oncol. 2004 Mar 1;22(5):909-18.

PMID:
14990647
48.

Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.

Haas NB, Giantonio BJ, Litwin S, Minniti CJ Jr, Fox S, Yeslow G, Reilly R, Nahum K, Greenberg R, Halbherr T, Hudes GR.

Cancer. 2003 Nov 1;98(9):1837-41.

49.

Treatments for improving survival of patients with prostate cancer.

David AK, Khwaja R, Hudes GR.

Drugs Aging. 2003;20(9):683-99. Review.

PMID:
12831292
50.

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ.

J Clin Oncol. 2003 Apr 1;21(7):1301-6.

PMID:
12663718

Supplemental Content

Loading ...
Support Center